Costco Pharmacy vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
NYSE: COST | $2.6B Rx revenue 2024 (11th largest US pharmacy); 19%+ prescription growth; below-market drug pricing open to non-members in most states; no PBM markup model
About
Costco Pharmacy operates as a pharmacy benefit integrated directly into Costco's warehouse membership model, offering prescription drug dispensing at significantly below-market prices by leveraging Costco's bulk purchasing power and low-margin retail philosophy. Founded as an extension of Costco Wholesale's membership warehouse business, the pharmacy operates on the principle that drug costs should be transparent and accessible, a differentiated stance in an industry dominated by opaque PBM pricing arrangements. Costco Pharmacy serves both Costco members and, in most states, non-members who can access the pharmacy counter without a warehouse membership.\n\nThe pharmacy operates across 650+ Costco warehouse locations in the United States, Puerto Rico, and internationally, offering a formulary of generic and brand-name prescription drugs at prices that often undercut major chains by 50–80%. Costco does not participate in most prescription drug insurance networks, which keeps overhead low and pricing simple — members pay a known cash price rather than navigating co-pay structures. The pharmacy also offers compounding services, pet medications, and immunizations at select locations, and integrates with Costco's optical and hearing aid departments to serve the full healthcare needs of its membership base.\n\nCostco Pharmacy is consistently ranked among the lowest-cost pharmacy options in independent drug pricing surveys, creating strong loyalty among members managing chronic conditions or high-cost specialty medications. The pharmacy benefits from Costco's 130 million+ cardholders globally, who view low-cost pharmacy access as one of the core value drivers of their membership. As PBM reform and drug pricing transparency become legislative priorities in the US, Costco's no-frills cash-pay model is increasingly viewed as a reference point for what pharmacy pricing could look like without intermediary markup layers.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.